Profile data is unavailable for this security.
About the company
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, formerly Tianjin Zhongxin Pharmaceutical Group Co Ltd, is a China-based company mainly engaged in the production, operation and scientific research of green traditional Chinese medicine. The Company's businesses cover the whole industry chain of traditional Chinese medicine, including the cultivation of Chinese medicinal materials, trade of Chinese medicinal materials, research and development (R&D), production and sales of Chinese patent medicines, production and sales of Chinese herbal decoction pieces, pharmaceutical commercial logistics, pharmaceutical retailing, chemical raw materials and preparations, biomedicine and many other fields. The Company's products include cardiovascular and cerebrovascular medicines, respiratory medicines, spleen and stomach medicines, cold medicines, oncology medicines, gynecological medicines, pediatric medicines and other other product groups.
- Revenue in USD (TTM)1.14bn
- Net income in USD129.30m
- Incorporated1981
- Employees11.00k
- LocationTianjin Pharmaceutical Da Ren Tang Group Corp LtdNo. 17, Baidi Road, Nankai DistrictTIANJIN 300193ChinaCHN
- Phone+86 2 227020892
- Fax+86 2 227020892
- Websitehttps://www.jydrt.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zai Lab Ltd | 322.66m | -298.28m | 3.06bn | 2.18k | -- | 4.29 | -- | 9.49 | -2.39 | -2.39 | 2.58 | 5.58 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| PTC Therapeutics, Inc. | 900.45m | -479.52m | 3.07bn | 988.00 | -- | -- | -- | 3.41 | -6.32 | -6.32 | 11.84 | -12.75 | 0.5534 | 2.16 | 4.94 | 911,390.70 | -29.47 | -26.71 | -44.23 | -33.46 | 92.35 | 93.94 | -53.25 | -83.80 | 2.17 | -1.12 | 1.70 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| China Resources Dubl-Crne Phrmctl Co Ltd | 1.58bn | 232.13m | 3.10bn | 12.27k | 13.20 | 2.16 | -- | 1.96 | 1.61 | 1.61 | 10.93 | 9.81 | 0.7106 | 3.04 | 6.08 | 914,865.00 | 10.54 | 8.40 | 14.70 | 11.08 | 56.34 | 58.19 | 14.83 | 11.98 | 1.26 | -- | 0.0633 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 1.14bn | 129.58m | 3.13bn | 11.00k | 14.27 | 2.09 | 21.76 | 2.75 | 0.1675 | 0.1675 | 1.47 | 1.15 | 0.7275 | 2.78 | 2.81 | -- | 8.13 | 8.96 | 13.60 | 12.76 | 44.45 | 40.16 | 11.18 | 10.67 | 1.26 | -- | 0.144 | 67.23 | -0.3266 | 5.24 | 14.49 | 11.93 | -4.33 | 42.45 |
| Tasly Pharmaceutical Group Co Ltd | 1.20bn | 123.75m | 3.14bn | 9.22k | 25.45 | 1.76 | -- | 2.61 | 0.5878 | 0.5878 | 5.73 | 8.51 | 0.4964 | 1.73 | 8.48 | 928,676.30 | 4.89 | 5.47 | 6.14 | 7.25 | 65.28 | 48.42 | 9.86 | 8.94 | 2.19 | 3.89 | 0.1766 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| Laurus Labs Ltd | 600.94m | 15.59m | 3.15bn | 6.01k | 201.92 | 6.40 | 48.58 | 5.24 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Virbac SA | -108.84bn | -108.84bn | 3.17bn | 5.46k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.70 | -- | 12.44 | -- | 65.61 | -- | 10.21 | -- | -- | -- | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
| HUTCHMED (China) Ltd | 610.70m | -41.96m | 3.18bn | 1.97k | -- | 4.30 | -- | 5.21 | -0.3881 | -0.3881 | 5.50 | 6.60 | 0.4775 | 7.10 | 4.15 | 2,387,889.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| Gland Pharma Ltd | 696.62m | 85.88m | 3.23bn | 4.22k | 37.67 | -- | 24.88 | 4.64 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Emcure Pharmaceuticals Ltd | -1.19bn | -1.19bn | 3.24bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management (Hong Kong) Co., Ltd.as of 30 Jun 2024 | 228.20k | 0.11% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 32.53k | 0.02% |
| Mellon Investments Corp.as of 30 Jun 2024 | 19.50k | 0.01% |
| Northern Trust Investments, Inc.(Investment Management)as of 03 Oct 2024 | 9.60k | 0.01% |
| CIBC Asset Management, Inc.as of 04 Oct 2024 | 1.10k | 0.00% |
| RAM Active Investments SAas of 30 Jun 2024 | 0.00 | 0.00% |
